AbCellera Biologics Inc. (ABCL) is in Healthcare, Biotechnology, based in Canada, listed on NasdaqGS. Market cap 3.90B USD. 52-week range 2.75 to 15.02 USD. Data as of 2026-10-09.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a ...